GlassScriptPhysician profile
Kong L Chang
NPI 1669429809
$7,232.22
in general payments reported to CMS, 2019-2025
19 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $410 · 2021: $1,537 · 2022: $1,222 · 2023: $1,060 · 2024: $922 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Entertainment: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.53 |
| Entertainment | $121.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,022.32 | 2020-2025 | Istent Infinite, Idosetr, Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $1,109.14 | 2022-2025 | Infuse, Infuse Multifocal, Biotrue One Day |
| Johnson & Johnson Vision Care, INC. | $1,092.01 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $696.79 | 2019-2021 | |
| Alcon Vision LLC | $471.38 | 2020-2025 | Total30, Precision7 |
| Eyevance Pharmaceuticals LLC | $434.10 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $319.51 | 2021-2022 | |
| New World Medical,INC. | $178.48 | 2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Optos, INC. | $175.49 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Rxsight INC | $145.75 | 2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Kala Pharmaceuticals, INC. | $120.36 | 2021 | |
| Shire North American Group INC | $118.16 | 2019 | |
| The Cameron-Ehlen Group, INC. | $117.90 | 2020 | |
| Allergan, INC. | $105.67 | 2022 | |
| Abb Con-Cise Optical Group LLC | $33.28 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $26.16 | 2019 | |
| Dompe US, INC. | $24.84 | 2025 | Oxervate |
| Abbvie INC. | $22.70 | 2023 | Lumigan |
| Astellas Pharma US INC | $18.18 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kong Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.